Highlander Health Announces Inaugural Investment of Target RWE
Highlander Health today announced the acquisition of Target RWE from existing investors, including 22C Capital.
Tune Therapeutics Receives Approval to Initiate Clinical Trial in Hong Kong for HepB Epigenetic Silencer
Leading epigenetic therapy company Tune Therapeutics announced today that it will begin a clinical trial in Hong Kong after receiving a Certificate for Clinical Trial from the Hong Kong Department of ...